Join Growin Stock Community!

Rani therapeutics holdings, inc.RANI.US Overview

US StockHealthcare
(No presentation for RANI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RANI AI Insights

RANI Overall Performance

RANI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RANI Recent Performance

-0.72%

Rani therapeutics holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RANI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RANI Key Information

RANI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RANI Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Price of RANI

RANI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RANI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
140.02
PB Ratio
23.87
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2359.58%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
140.02
PB Ratio
23.87
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2359.58%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RANI's latest earnings report released?

    The most recent financial report for Rani therapeutics holdings, inc. (RANI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RANI's short-term business performance and financial health. For the latest updates on RANI's earnings releases, visit this page regularly.

  • How much debt does RANI have?

    As of the end of the reporting period, Rani therapeutics holdings, inc. (RANI) had total debt of 17.55M, with a debt ratio of 1.73. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RANI have?

    At the end of the period, Rani therapeutics holdings, inc. (RANI) held Total Cash and Cash Equivalents of 4.14M, accounting for 0.41 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RANI's EPS continuing to grow?

    According to the past four quarterly reports, Rani therapeutics holdings, inc. (RANI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RANI?

    Rani therapeutics holdings, inc. (RANI)'s Free Cash Flow (FCF) for the period is -5.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 40.68% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.